Jun212021 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome June 21, 2021
May72021 Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit May 7, 2021
May52021 Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development May 5, 2021
Apr262021 Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference April 26, 2021
Apr122021 Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome April 12, 2021
Feb112021 Anavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook February 11, 2021
Feb82021 Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021 February 8, 2021
Jan62021 Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference January 6, 2021
Dec282020 Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates December 28, 2020
Dec222020 Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020 December 22, 2020
Dec212020 Anavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX®2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co. December 21, 2020
Dec152020 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome December 15, 2020
